Results 201 to 210 of about 234,795 (273)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis. [PDF]

Dermatol Ther (Heidelb)
Crowley J, Song EJ, Stein-Gold L, Gisondi P, Bunick CG, Garg V, Leoncini E, Kaplan B, Ta R, Truong B, Sharma D, Strober B.   +11 more
europepmc   +1 more source

Stellate ganglion block achieves remission of recurrent head-and-neck plaque psoriasis: A case report. [PDF]

J Int Med Res
Liu J, Zhang Z, Liu T.
europepmc   +1 more source

Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. [PDF]

Cureus
Abdullah A, Polus L.
europepmc   +1 more source

SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study. [PDF]

Front Immunol
Cai L, Chen J, Wu L, Duan X, Zhang G, Li Y, Zhang L, Qin L, Zeng T, Wang X, Wang J, Huang K, Ren H, Liu L, Ding Y, Cui Y, Shan Y, Lu J, Tao X, Chen R, Tu Y, Yan M, Zhu X, Qiao N, Meng Z, Wang Y, Cheng F, Yuan Y, Zhu J, Hu X, Guo S, Xia X, Man X, Wu Z, Chen X, Chen G, He Y, Lv D, Feng Y, Deng D, Geng S, Guo Q, Feng W, Zhu X, Liu Y, Lin B, Xia R, Yu C, Fan J, Ji M, Lei T, Yang W, Yang M, Gao Y, Li W, Jiang M, Lou J, Liu Y, Zhou C, Zhang J.   +59 more
europepmc   +1 more source

Severe plaque psoriasis exacerbation during lenalidomide maintenance after autologous stem cell transplantation for multiple myeloma. [PDF]

JAAD Case Rep
Mousa AM, Mahmoud-Katheer M, El Hariri M, Khazal M, Khudadah K, AlShuraiaan GM.   +5 more
europepmc   +1 more source

Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials. [PDF]

Am J Clin Dermatol
Armstrong AW, Lebwohl M, Warren RB, Morita A, Paul C, Thaçi D, Augustin M, Puig L, Daamen C, Li J, Alió A, Aggrey-Amable A, Scotto J, Popmihajlov Z, Vaile J, Strober B.   +15 more
europepmc   +1 more source

A systems-oriented Ayurvedic approach in chronic plaque psoriasis with renal inflammatory indicators: a 2-year longitudinal case report. [PDF]

Front Med (Lausanne)
Mallika S, Menon A, Unnikrishnan V, Mohan P.   +3 more
europepmc   +1 more source

Real-life effectiveness and safety of bimekizumab in patients with moderate plaque psoriasis: a 54-week multicentre study in the Lazio region. [PDF]

Drugs Context
Feresin F, Bernardini N, Campione E, Caldarola G, Gubinelli E, Moretta G, Pagnanelli G, Giordano D, Persechino S, Falco GM, Artosi F, Zappia E, Pellacani G, Potenza C, Richetta AG, De Simone C, Orsini D, Dattola A.   +17 more
europepmc   +1 more source

Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials. [PDF]

Front Immunol
Xin T, Sun S, Liu Y.
europepmc   +1 more source

Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study. [PDF]

Front Med (Lausanne)
Zhang Z, Zhang B, Wen Y, Hu Q, Jiang W, Zhuo J, Luo G, Wang Y.   +7 more
europepmc   +1 more source